MedTrace Logo

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01024322 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1189

Last updated 2018-10-11

No results posted yet for this study

Summary

To evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication

Conditions

  • Keratoconus
  • Ectasia
  • Degeneration

Interventions

DRUG

Ciprofloxicine or Vigamox or other.

Ciprofloxicine or Vigamox or other to be used qid till epithelialized.

DRUG

Nonsteroidal (Acular, Voltaren Xibrom, etc)

Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op

DRUG

Steroid (FML, Pred Forte, Flarex, etc.)

Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.

Sponsors & Collaborators

  • Cxlusa

    lead INDUSTRY

Principal Investigators

  • William Trattler, MD · The Center for Excellence in Eye Care

  • Roy Rubinfeld, MD · Re: Vision

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-01
Primary Completion
2017-02-03
Completion
2017-02-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024322 on ClinicalTrials.gov